No takes yet. Share an insight, caveat, or question.
Preclinical study demonstrates quality compliance and potent immune responses of CTVad1 adjuvant in animal models, highlighting readiness for human trials.
Assis et al. (2023) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: